Advertisement

PharmacoEconomics & Outcomes News

, Volume 836, Issue 1, pp 15–15 | Cite as

Influenza vaccination for age 50−64 cost beneficial in Australia

Clinical study
  • 8 Downloads

Reference

  1. Raj SM, et al. Cost-benefit analysis of a national influenza vaccination program in preventing hospitalisation costs in Australian adults aged 50-64 years old. Vaccine : 28 Aug 2019. Available from: URL: http://doi.org/10.1016/j.vaccine.2019.08.028

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations